Teva Pharmaceuticals

Teva Pharmaceuticals, headquartered in Israel and operating in the Pharmaceutical Preparation Manufacturing industry, has set ambitious climate targets and reported its carbon emissions.

In 2025, Teva Pharmaceuticals reported total Scope 1, 2, and 3 emissions of approximately 3.3 billion kg CO2e. This includes Scope 1 emissions of 229,331,000 kg CO2e, market-based Scope 2 emissions of 161,989,000 kg CO2e, and Scope 3 emissions of about 2.9 billion kg CO2e. Key categories contributing to Scope 3 include purchased goods and services (2,172,650,000 kg CO2e), use of sold products (715,334,000 kg CO2e), and end-of-life treatment of sold products (427,841,000 kg CO2e).

Looking back, in 2024, the company's total emissions were approximately 3.7 billion kg CO2e, with Scope 1 at 241,128,000 kg CO2e, market-based Scope 2 at 207,915,000 kg CO2e, and Scope 3 at about 3.3 billion kg CO2e. In 2023, total emissions were around 3.6 billion kg CO2e, comprising Scope 1 emissions of 238,956,000 kg CO2e, market-based Scope 2 emissions of 229,970,000 kg CO2e, and Scope 3 emissions of approximately 3.1 billion kg CO2e.

Teva Pharmaceuticals has committed to several reduction targets validated by the Science Based Targets initiative (SBTi). The company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 46.2% by 2030, using a 2019 base year. Additionally, Teva Pharmaceuticals plans to reduce absolute Scope 3 GHG emissions by 25% by 2030, compared to a 2020 base year. The company has also stated its intention to achieve net-zero emissions across its operations and value chain by 2045. As of 2023, Teva Pharmaceutical Industries Ltd. is listed by SBTi as having "Targets Set" with a "1.5°C" near-term target classification.